Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. The GLP-2 derivative or a conjugate thereof are useful in preventing or treating one or more diseases selected from intestinal disease, intestinal injury, or gastrosia. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.
Type:
Application
Filed:
November 2, 2022
Publication date:
March 23, 2023
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Jaehyuk CHOI, Min Young KIM, In Young CHOI, Sung Youb JUNG
Abstract: Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
February 28, 2023
Assignee:
BEIJING HANMI PHARM. CO., LTD.
Inventors:
Jiawang Liu, Nanmeng Song, Yaping Yang, Mengxie Jin
Abstract: An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.
Type:
Application
Filed:
January 22, 2021
Publication date:
February 23, 2023
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Bo Sik KIM, Hyuk Jun CHO, Ho Taek IM, Yong II KIM
Abstract: A composition containing a glucagon derivative and a GLP-1 and GIP receptor dual agonist, and uses thereof are disclosed. The glucagon derivative comprises an amino acid sequence of the formula 1: X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-X24-WL-X27-X28-X29-X30 (Formula 1). The composition is useful in preventing or treating metabolic syndrome.
Type:
Application
Filed:
October 5, 2020
Publication date:
January 5, 2023
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Jung Kuk KIM, Jong Suk LEE, A Ram LEE, Joo Young DONG
Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.
Type:
Grant
Filed:
March 27, 2020
Date of Patent:
December 20, 2022
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Jaehyuk Choi, Min Young Kim, In Young Choi, Sung Youb Jung
Abstract: The present invention relates to a pharmaceutical preparation comprising a granule comprising a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a diluent. The pharmaceutical preparation has a high productivity of the preparation due to excellent tableting properties, friability, and mass uniformity. The pharmaceutical preparation has low generated amount of impurities and high stability.
Type:
Application
Filed:
October 23, 2020
Publication date:
December 1, 2022
Applicant:
Hanmi Pharm Co., Ltd.
Inventors:
Young II Kim, Taek Kwan Kwon, Ho Taek Im, Yong II Kim
Abstract: A physiologically active polypeptide-immunoglobulin Fc fragment conjugate and a method for making the conjugate are disclosed. The conjugate contains a physiologically active polypeptide linked via a non-peptidyl linker to an immunoglobulin Fc fragment having an FcRn-binding region and maintains the intrinsic binding affinity of the immunoglobulin Fc fragment. A method of maintaining the intrinsic binding affinity of the conjugate for FcRn, and a composition containing the conjugate, which maintains the intrinsic binding affinity of the immunoglobulin Fc fragment for FcRn are also disclosed.
Type:
Application
Filed:
August 3, 2022
Publication date:
December 1, 2022
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Sang Youn HWANG, Jong Soo Lee, Sung Hee Hong, In Young Choi, Sung Youb Jung, Se Chang Kwon
Abstract: Composition including GLP-2 or a long-acting conjugate thereof and uses thereof are disclosed. The composition including GLP-2 or a long-acting conjugate thereof is useful for preventing or treating metabolic bone diseases.
Type:
Application
Filed:
December 24, 2020
Publication date:
November 17, 2022
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Jae Hyuk CHOI, Jin Bong LEE, Sang Hyun LEE, Sang Don LEE, Min Young KIM
Abstract: The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.
Type:
Grant
Filed:
November 29, 2018
Date of Patent:
November 8, 2022
Assignee:
Hanmi Pharm. Co., Ltd.
Inventors:
In Hwan Bae, Seung Hyun Jung, Young Gil Ahn, Kwee Hyun Suh
Abstract: A method of preparing a protein conjugate contains linking a mono-PEGylated immunoglobulin Fc region to a dual agonist exhibiting activity on both GLP-1 and glucagon. The mono-PEGylated immunoglobulin Fc region is prepared by linking a linker of Formula 1 to the N-terminus of an immunoglobulin Fc region comprising a hinge sequence: CHO-L1-(OCH2CH2)nO-L2-R.
Type:
Application
Filed:
July 18, 2019
Publication date:
September 1, 2022
Applicant:
HANMI PHARM. CO., LTD
Inventors:
Cheongbyeol SHIN, Dooseo JANG, Ji Hye MOON, Dong Hyun KIM, Ji Eun LEE
Abstract: Provided are a protein conjugate in which a physiologically active polypeptide is linked to a biocompatible material via a non-peptidyl polymer-coupled fatty acid derivative compound serving as a linker, exhibiting an increased duration of physiological activity compared to natural forms and a preparation method therefor. Since an increase in serum half-life of the physiologically active polypeptide of the protein conjugate, in which the biocompatible material, the non-peptidyl polymer-coupled fatty acid derivative compound, and the physiologically active polypeptide are linked, is proved, the protein conjugate may be widely used in the field of protein drugs.
Type:
Application
Filed:
May 6, 2022
Publication date:
August 18, 2022
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Su Yeon PARK, Ji Young SONG, Eun Jung KIM, Jong Min LEE, Jong-Soo LEE, Dae Jin KIM
Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.
Type:
Application
Filed:
April 27, 2022
Publication date:
August 11, 2022
Applicant:
HANMI PHARM. CO., LTD
Inventors:
Dae Jin KIM, Jong Soo LEE, Young Jin PARK, Sung Hee HONG, Sung Min BAE, Se Chang KWON
Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.
Type:
Application
Filed:
April 14, 2022
Publication date:
August 11, 2022
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Jaehyuk Choi, Min Young Kim, In Young Choi, Sung Youb Jung
Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex prepared by the present invention may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.
Type:
Grant
Filed:
September 26, 2016
Date of Patent:
July 19, 2022
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Dae Jin Kim, Jong Soo Lee, Young Jin Park, Sung Hee Hong, Sung Min Bae, Se Chang Kwon
Abstract: The present disclosure relates to a pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, and particularly to a pharmaceutical composition which exhibits a dual release profile of immediate release and sustained release so that long-term efficacy can be sustained. The pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, according to the present disclosure, can secure bioavailability equivalent to that of existing esomeprazole immediate-release/enteric-release formulations, and can maintain long-term efficacy due to the dual release profile thereof even when administered once a day, thus preventing the occurrence of nocturnal acid breakthrough, and accordingly, can be effectively used as a therapeutic agent for nocturnal acid breakthrough.
Type:
Application
Filed:
April 1, 2020
Publication date:
June 30, 2022
Applicant:
HANMI PHARM. CO., LTD
Inventors:
Hyuk Jun CHO, Taek KWON, Ho Taek IM, Yong ll KIM, Jin A JUNG, Han Kil SON, Sung Hee HONG